AU2005263729B2 - Use of compounds containing thiol groups as an efflux pump inhibitor - Google Patents

Use of compounds containing thiol groups as an efflux pump inhibitor Download PDF

Info

Publication number
AU2005263729B2
AU2005263729B2 AU2005263729A AU2005263729A AU2005263729B2 AU 2005263729 B2 AU2005263729 B2 AU 2005263729B2 AU 2005263729 A AU2005263729 A AU 2005263729A AU 2005263729 A AU2005263729 A AU 2005263729A AU 2005263729 B2 AU2005263729 B2 AU 2005263729B2
Authority
AU
Australia
Prior art keywords
thiol group
group containing
thiolated
drugs
thiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005263729A
Other languages
English (en)
Other versions
AU2005263729A1 (en
Inventor
Martin Hoffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bey Pharma GmbH
THIOMATRIX FORSCHUNGS-UND BERATUNGS GmbH
Original Assignee
Bey Pharma GmbH
ThioMatrix Forschungs und Beratungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bey Pharma GmbH, ThioMatrix Forschungs und Beratungs GmbH filed Critical Bey Pharma GmbH
Publication of AU2005263729A1 publication Critical patent/AU2005263729A1/en
Application granted granted Critical
Publication of AU2005263729B2 publication Critical patent/AU2005263729B2/en
Assigned to THIOMATRIX FORSCHUNGS-UND BERATUNGS GMBH, Bey Pharma GmbH reassignment THIOMATRIX FORSCHUNGS-UND BERATUNGS GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: MUCOBIOMER BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGS GMBH, THIOMATRIX FORSCHUNGS-UND BERATUNGS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005263729A 2004-07-22 2005-07-14 Use of compounds containing thiol groups as an efflux pump inhibitor Ceased AU2005263729B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1250/2004 2004-07-22
AT12502004 2004-07-22
PCT/EP2005/053395 WO2006008270A1 (de) 2004-07-22 2005-07-14 Verwendung von thiolgruppen-hältigen verbindungen als efflux-pumpen-hemmer

Publications (2)

Publication Number Publication Date
AU2005263729A1 AU2005263729A1 (en) 2006-01-26
AU2005263729B2 true AU2005263729B2 (en) 2011-01-06

Family

ID=34981500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005263729A Ceased AU2005263729B2 (en) 2004-07-22 2005-07-14 Use of compounds containing thiol groups as an efflux pump inhibitor

Country Status (7)

Country Link
US (1) US20080200563A1 (enExample)
EP (1) EP1768676A1 (enExample)
JP (1) JP2008506750A (enExample)
CN (1) CN101035547A (enExample)
AU (1) AU2005263729B2 (enExample)
CA (1) CA2574232A1 (enExample)
WO (1) WO2006008270A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2107913T1 (sl) 2006-12-22 2012-05-31 Croma Pharma Ges M B H Uporaba tioliranih polisaharidov za tkivno avgmentacijo
EP2296637B1 (en) 2008-04-24 2014-04-02 Medtronic, Inc Chitosan-containing protective composition
US9198997B2 (en) 2008-04-24 2015-12-01 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
EP2310002B1 (en) 2008-04-24 2016-11-02 Medtronic, Inc Protective gel based on chitosan and oxidized polysaccharide
EP2288389B1 (en) 2008-04-24 2014-06-11 Medtronic, Inc Cold ionizing radiation sterilization
KR101673042B1 (ko) 2009-03-12 2016-11-04 키바이오사이언스 아게 당뇨병 및 대사 증후군의 치료
EP3095484B1 (en) 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
MX351092B (es) 2011-11-02 2017-10-02 Keybioscience Ag Analogos peptidicos para tratar enfermedades y trastornos.
KR20160075794A (ko) 2013-11-14 2016-06-29 키바이오사이언스 아게 질환 및 질병 치료용 칼시토닌 모방체
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420733B (sv) * 1974-05-30 1981-10-26 Exploaterings Ab Tbf Gelprodukt, innehallande tiosulfatgrupper samt sett for framstellning derav
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5523316A (en) * 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
IT1282625B1 (it) * 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5696152A (en) * 1996-05-07 1997-12-09 Wisconsin Alumni Research Foundation Taxol composition for use as organ preservation and cardioplegic agents
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
JP4827385B2 (ja) * 2004-04-07 2011-11-30 ロート製薬株式会社 アズレン含有水性液剤

Also Published As

Publication number Publication date
CN101035547A (zh) 2007-09-12
EP1768676A1 (de) 2007-04-04
JP2008506750A (ja) 2008-03-06
US20080200563A1 (en) 2008-08-21
AU2005263729A1 (en) 2006-01-26
WO2006008270A1 (de) 2006-01-26
CA2574232A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ES2893444T3 (es) Formulaciones de posaconazol en solución intravenosa estabilizadas mediante beta-ciclodextrina sustituida
AU700021B2 (en) Biological agent compositions
US20080200563A1 (en) Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
CN102215874A (zh) 活性剂的聚合物递送系统
Li et al. Oral delivery of imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption
EP2307056A2 (en) Stabilized aqueous formulation containing paracetamol
US20160022716A1 (en) Compositions and methods for treating huntingtons disease
US20250073170A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
MX2010006927A (es) Composiciones farmaceuticas que contienen al menos un ingrediente activo de proteina protegido contra las enzimas digestivas.
ES3031815T3 (en) Antimicrobial compositions containing polyquaternium
US20030211072A1 (en) Compositions with enhanced oral bioavailability
JP2001261564A (ja) アジスロマイシンのバイオアベイラビリティ及び組織浸透性を増加させる方法
US20180015074A1 (en) Use of mtor inhibitors to prevent and regress edhesions and fibrosis
TWI887279B (zh) 腎毒素引起的腎損傷的治療和預防
RU2542449C2 (ru) Композиции и способы лечения рака мочевого пузыря
WO2011104625A1 (en) Cyclopolysaccharide compositions
US20180369389A1 (en) Novel anticancer pharmaceutical nanoformulation and method of preparing same
KR102455423B1 (ko) 펜벤다졸 가용화 조성물 및 이의 용도
EP3025733A1 (en) Pharmaceutical, water-soluble and antifungal macromolecular compound
EP3928835B1 (en) Water-soluble polymeric derivative of venetoclax
JP2024534403A (ja) 眼疾患のための緑茶ベースのナノコンプレックス
WO2019162756A2 (en) Liquid pharmaceutical compositions of anticancer drugs
EP3049078B1 (en) Treatment of cancer
EA021117B1 (ru) Способ получения водорастворимой фармацевтической композиции антибиотика из группы рифамицинов и фармацевтическая композиция для лечения туберкулеза и заболеваний, связанных с helicobacter pylori
JP4287523B2 (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired